Bio-Rad Labs (BIO) Tops Q3 EPS by $1.20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bio-Rad Reports Third-Quarter 2020 Financial Results
October 29, 2020 4:15 PM EDTHERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2020.
Third-quarter 2020 net sales were $647.3 million, an increase of 15.5 percent compared to $560.6 million reported for the third quarter of 2019. On a currency-neutral basis, quarterly sales increased 14.9 percent compared to the same period in 2019. Third-quarter gross margin was 56.7 percent compared to 54.8 percent during the third quarter in 2019.
Life Science segment net sales for the third quarter were $324.0 million, an increase of 50.2 percent compared to the... More
